Title: Diagnostic accuracy of DNA-based SDC2 methylation test in colorectal cancer screening:
a meta-analysis
Version: 1 Date: 24 Jan 2022
Reviewer's report:
1. Multitarget stool DNA (MT-sDNA) every three years was approved by the US Food and
Drug Administration (FDA) in 2014. (Jaklevic MC. JAMA 2021;325:116-118.) The DNA
test includes quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3
methylation, and #-actin.
The sensitivity of MT-sDNA for CRC was 92.3%, and for stage I-III CRC was 93.3%. The
AUC for CRC was 0.94 (N Engl J Med 2014;370:1287-97). The authors should compare SDC2
methylation and MT-sDNA.
2. In the “Abstract” section, the authors should Initially use the word “SDC2” in full, not use
the abbreviation
3. In the “Abstract” section, the authors should describe clearly the sensitivity, specificity,
positive likelihood ratio, and negative likelihood ratio were for adenoma, early CRC, or CRC.
4. In the “Data extraction” section, what did tp, fp, fn, and tn mean?
Title: Diagnostic accuracy of DNA-based SDC2 methylation test in colorectal cancer screening:
a meta-analysis
Version: 1 Date: 24 Jan 2022
Reviewer's report:
1. Multitarget stool DNA (MT-sDNA) every three years was approved by the US Food and
Drug Administration (FDA) in 2014. (Jaklevic MC. JAMA 2021;325:116-118.) The DNA
test includes quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3
methylation, and #-actin.
The sensitivity of MT-sDNA for CRC was 92.3%, and for stage I-III CRC was 93.3%. The
AUC for CRC was 0.94 (N Engl J Med 2014;370:1287-97). The authors should compare SDC2
methylation and MT-sDNA.
2. In the “Abstract” section, the authors should Initially use the word “SDC2” in full, not use
the abbreviation
3. In the “Abstract” section, the authors should describe clearly the sensitivity, specificity,
positive likelihood ratio, and negative likelihood ratio were for adenoma, early CRC, or CRC.
4. In the “Data extraction” section, what did tp, fp, fn, and tn mean?
Please review this paper.
user
Title: Diagnostic accuracy of DNA-based SDC2 methylation test in colorectal cancer screening:
a meta-analysis
Version: 1 Date: 24 Jan 2022
Reviewer's report:
1. Multitarget stool DNA (MT-sDNA) every three years was approved by the US Food and
Drug Administration (FDA) in 2014. (Jaklevic MC. JAMA 2021;325:116-118.) The DNA
test includes quantitative molecular assays for KRAS mutations, aberrant NDRG4 and BMP3
methylation, and #-actin.
The sensitivity of MT-sDNA for CRC was 92.3%, and for stage I-III CRC was 93.3%. The
AUC for CRC was 0.94 (N Engl J Med 2014;370:1287-97). The authors should compare SDC2
methylation and MT-sDNA.
2. In the “Abstract” section, the authors should Initially use the word “SDC2” in full, not use
the abbreviation
3. In the “Abstract” section, the authors should describe clearly the sensitivity, specificity,
positive likelihood ratio, and negative likelihood ratio were for adenoma, early CRC, or CRC.
4. In the “Data extraction” section, what did tp, fp, fn, and tn mean?
assistant